|Bid||145.80 x 100|
|Ask||145.88 x 200|
|Day's Range||145.41 - 146.77|
|52 Week Range||114.53 - 194.66|
|PE Ratio (TTM)||6.42|
|Dividend & Yield||1.36 (0.93%)|
|1y Target Est||N/A|
Drug distributors are down about 9% in the past two weeks as investors fret about generic deflation concerns. Morgan Stanley’s Ricky Goldwasser and his team write that without near term catalysts, the stocks are probably going to remain range bound in the near future. Goldwasser writes that competition could escalate, as the Food and Drug Administration approve pending applications from additional manufacturers.
McKesson (MCK) entered fiscal 2018 with an assumption of branded inflation in the mid-single digits. Pricing pressure in the independent retail pharmacy channel is a headwind.
Cantor Fitzgerald says Allscripts acquisition of McKesson's Enterprise Information Solutions will provide it material cost saving opportunities.